Below are just some of the more recent references to TB...

Below are just some of the more recent references to TB Tuberculosis, drug resistant and/or co-infection HIV/AIDS, giveing good reason as to why Immunoxel should be fast tracked as soon as possible as recently stated by STI :

Conclusions Immunoxel :

One of the key botanical product range that the joint venture is focused on introducing to global markets is Immunoxel, a proven immunomodulator and very effective complementary agent in the treatment of tuberculosis (?TB?), a highly contagious condition and major scourge within mainly developing countries and a serious health threat to the western world. Approximately a third of the world?s population now carries the TB bacteria. Extensive clinical trials show that Immunoxel significantly enhances the effects of anti-TB and anti-TB/HIV drugs and protects the liver from drug related toxicity. Importantly, Immunoxel has demonstrated significant effectiveness against the rapidly emerging drug resistant strains of TB.

Conclusions from V5 Phase 11b Trials :

V5 is shown to be safe and capable of reversing ATT associated hepatotoxicity. In addition, V5 reduces the inflammation as evidenced by several hematological and biochemical markers. Weight gain and sputum smear conversion rate have been significantly enhanced as compared to conventional ATT. As evidenced by obtained improvements the combination of V5 and ATT can shorten substantially the duration of treatment.

Our preliminary findings need to be explored further in a larger population of patients followed for longer periods of time to establish the usefulness of V5 as a therapeutic TB vaccine.

Considering that 2 billion people are latently infected with M. tuberculosis, it is likely that two different types of prophylactic TB vaccines will be needed: one is so called pre-exposure vaccine to prevent mycobacterial infection in na?ve individuals and second, post-exposure vaccine, to prevent TB disease in tubercle bacilli carriers without exacerbating disease manifestations. Up to now, the majority of vaccine candidates are in the first category and only M. vaccae and RUTI are considered to be in the second category [35]. Studying V5 as post-exposure vaccine can contribute to better understanding of the immunopathogenesis of TB resulting in the design of effective vaccines and accelerate evaluation of their efficacy. In addition, V5 studies can yield important insights into correlates of immune protection, which are still poorly understood.

RE INDIA, RUSSIA/UIKRAINE, (not including Africa & some other high infected countries) and then AUSTRALIA.

Indian newspaper 19th June, 2011 : Reference to fast growing numbers of TB infections (in India 1.8 million new each year) and reference to TB/HIV/AIDS co-infections and outdated treatment/lack of treatment and cost :

http://www.deccanherald.com/content/170052/tb-treatment-needs-much-focus.html
Full version if you can get that damn Indian Domino?s pizza popup to stay out the way.

Extracts :

Bharathi Ghanashyam Sunday, June 19, 2011 --> The most commonly used test for TB is still the smear microscopy which is as old as TB itself. The week that has passed has been significant for the HIV/AIDS sector. It marked the 30th anniversary of the AIDS epidemic. World leaders gathered for a high level meeting on AIDS in New York and according to reports, a scientific blueprint for interventions that will enable us to save a million more lives by 2015 was unveiled. The Stop TB Partnership released new scientific modelling at the meeting, which shows that with aggressive use of existing technology and tested interventions, TB-HIV deaths can...

It?s time to pause and ask some questions here. What about those who are TB infected but not HIV positive? Who speaks for them? According to revised national tuberculosis control programme (RNTCP) India has around 1.8 million new cases of TB every year and more than 3.7 lakh people die of TB every year in India How many of these are not HIV positive? What do health systems have in place to save these lives? These are questions that we desperately need to find answers to, even as we save a million precious lives that will suffer from the co-infections of HIV/TB. It is time to give TB the same attention that HIV gets, and take it to international forums with the same vigour and activism that HIV has managed to do.


References to childhood TB and treatment, immunization, problems
http://in.reuters.com/article/2011/06/22/us-tuberculosis-vaccine-idINTRE75L5LY20110622

TB is currently a worldwide pandemic that kills around 1.7 million people a year. The infection is caused by the bacterium Mycobacterium tuberculosis and destroys patients' lung tissue, causing them to cough up the bacteria, which then spread through the air and can be inhaled by others.

TB EVEN HAS IT?S OWN PHOTO AWARDS : references Russia

http://www.stoptb.org/news/stories/2011/ns11_046.asp
2011 Images to Stop Tuberculosis photo award invites entries
IF you want to view the photo?s 2010 award, (some not for the light hearted) http://www.stoptb.org/global/awards/images/awardees/default.asp
It references the Ukraine
Then click on the ?see the photo reportage [.pdf]?

Reference to the Global Fund : strategies to fight Aids, Teberculosis & Malaria
http://www.who.int/pmnch/about/steering_committee/b10-11_item4.c_globalfund_ruwan_de_mel.pdf
$30 billion in donor support,

Partnership ForumSao Paulo 26-30 June 2011,
Regional/thematic consultationsTo be scheduled for July/August 2011

Tuberculosis: THE THREAT TO AUSTRALIA : Increasing

The Australian 30th May, 2011

http://www.abc.net.au/rn/lifematters/stories/2011/3235112.htm
listen now | download audio Click on the audio link

Reference to TB infections/lack of treatment Torrens Islanders etc.
http://www.theaustralian.com.au/national-affairs/calls-to-keep-torres-strait-tb-clinics-open/story-fn59niix-1226065194934

Another reference to TB in Australia
http://www.australianprescriber.com/magazine/33/1/12/18/

RE : WORLD WIDE MEETINGS TO COMBAT TB. :

http://www.grc.org/programs.aspx?year=2011&program=tuberc

Innovating on a Shoestring: Medical Technologies for the Developing World
30-Jun-2011 | New York Academy of Sciences, New York, NY, USA

Gordon Research Conference -- TB Drug Development
3-Jul-2011 - 8-Jul-2011 | Lucca (Barga), Italy

Advanced TB Diagnostic Research: An intensive,
high-level course on TB diagnostic research methods
5-Jul-2011 - 8-Jul-2011 | Montreal, Quebec, Canada

3rd Conference of The Union Asia-Pacific Region:
Current Challenges in Tuberculosis and Lung Health
8-Jul-2011 - 11-Jul-2011 | Hong Kong, China

4th International Workshop on Clinical Pharmacology of
Tuberculosis Drugs
16-Sep-2011 | Chicago, Illinois, USA

51th Interscience Conference on Antimicrobial Agents and
Chemotherapy (ICAAC)
17-Sep-2011 - 20-Sep-2011 | Chicago, Illinois

42nd Union World Conference on Lung Health
26-Oct-2011 - 30-Oct-2011 | Lille, France

Finally : Here?s a question asked on ?i-base? re immunoxel in 2009 :

(Well the answer could be nearly there, shortly ?)

Question

Will Immunoxel and dermavir patches be available in the UK?

I would like to thank everyone involved at i-Base as the information I have found here has been so helpful as have just been diagnosed 1 month ago with HIV as am a lot less scared now and has helped me deal with my situation.
I have 2 qeustions. Firstly, when will immunoxel be available in the UK?

Also the dermavir patch, what are your thoughts, will it be with antiretrovirals or without, also how long do you think until it will be approved here, in the UK?
once angain thanks look forward to your reply

4 July 2009 ? Related: All topics, General, Supplements and herbs

Answer

Hi, thanks for the nice words.

Generally, there are no plans for dermavir patches to be used with ARVs. So its, use in the near future is highly unlikely.

As for Immunoxel, it is an Ukrainian product that may never make it to the UK, unless it does not go through stringent clinical studies in the West, so that it proves its effectiveness. This may take many years.

Answer: Svilen Konov
Comments are closed.

As always do your own research, make your own decisions.